Koji Matsuo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5378769/publications.pdf

Version: 2024-02-01

393 papers	8,940 citations	61984 43 h-index	76900 74 g-index
399 all docs	399 docs citations	399 times ranked	10617 citing authors

#	Article	IF	Citations
1	Prior vertical uterine incision: Effect on subsequent pregnancy characteristics and outcomes. International Journal of Gynecology and Obstetrics, 2023, 160, 85-92.	2.3	4
2	Metastatic extent-specific prognosis of women with stage IVB cervical cancer: multiple versus single distant organ involvement. Archives of Gynecology and Obstetrics, 2023, 307, 533-540.	1.7	3
3	Utilization of sentinel lymphÂnode biopsy in the early ovarian cancer surgery. Archives of Gynecology and Obstetrics, 2023, 307, 525-532.	1.7	5
4	Prevalence of anxiety and depressive disorders in pregnant women with malignancy. International Journal of Gynecology and Obstetrics, 2023, 160, 635-640.	2.3	2
5	Association between hysterectomy wait-time and all-cause mortality for micro-invasive cervical cancer: treatment implications during the coronavirus pandemic. Archives of Gynecology and Obstetrics, 2022, 306, 283-287.	1.7	3
6	Effects of aspirin and statin use on venous thromboembolism prophylaxis and survival in patients with endometrial cancer. Expert Opinion on Drug Safety, 2022, 21, 335-347.	2.4	0
7	In reply: Is twin gestation an independent risk factor for placenta accreta spectrum?. American Journal of Obstetrics and Gynecology, 2022, 226, 447-448.	1.3	2
8	Proposal of a simple 2-hand technique at cesarean hysterectomy for placenta accreta spectrum. Archives of Gynecology and Obstetrics, 2022, 305, 1-5.	1.7	3
9	Sentinel lymph node biopsy for vulvar melanoma: trends in tumor stage-specific utilization. American Journal of Obstetrics and Gynecology, 2022, 226, 438-440.	1.3	4
10	Racial and ethnic disparity in characteristics and outcomes of women with placenta accreta spectrum: a comparative study. Reproductive Sciences, 2022, 29, 1988-2000.	2.5	5
11	Incorporation of vaginal brachytherapy to external beam radiotherapy in adjuvant therapy for high-risk early-stage cervical cancer: A comparative study. Brachytherapy, 2022, 21, 141-150.	0.5	1
12	Sentinel lymph node biopsy for stage II endometrial cancer: Recent utilization and outcome in the United States. Gynecologic Oncology, 2022, 164, 46-52.	1.4	12
13	Hospital surgical volumeâ€"outcome relationship in caesarean hysterectomy for placenta accreta spectrum. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 986-993.	2.3	4
14	Trends, characteristics, and outcomes of conservative management for placenta percreta. Archives of Gynecology and Obstetrics, 2022, 306, 913-920.	1.7	6
15	Population-level trends and outcomes of sentinel lymph node biopsy in vulvar cancer surgery in the United States. Gynecologic Oncology, 2022, 164, 651-657.	1.4	6
16	Validation of the 2021 FIGO staging schema for advanced vulvar cancer. International Journal of Gynecological Cancer, 2022, 32, 474-479.	2.5	5
17	Conservative management of placenta percreta: is current evidence sufficient?. American Journal of Obstetrics and Gynecology, 2022, , .	1.3	0
18	Authors' reply re: Covariate analysis query: Hospital surgical volumeâ€•outcome relationship in caesarean hysterectomy for placenta accreta spectrum. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, , .	2.3	0

#	Article	IF	Citations
19	Can topographic classification of placenta accreta spectrum disorders predict the need for endovascular arterial occlusion during surgery?. Acta Obstetricia Et Gynecologica Scandinavica, 2022, , .	2.8	0
20	Significance of histology and nodal status on the survival of women with early-stage cervical cancer: validation of the 2018 FIGO cervical cancer staging system. Journal of Gynecologic Oncology, 2022, 33, .	2.2	0
21	Characterizing isolated tumor cells in regional lymph nodes of early endometrial cancer. Gynecologic Oncology, 2022, 165, 264-269.	1.4	4
22	Hormonal therapy or chemotherapy for early-stage, low-grade endometrial cancer with malignant peritoneal cytology: A comparative effectiveness study. Gynecologic Oncology, 2022, , .	1.4	1
23	Incorporation of sentinel lymph node biopsy in cervical cancer surgery: Recent U.S. trends. European Journal of Surgical Oncology, 2022, 48, 1407-1413.	1.0	6
24	Treatment specialtyâ€specific characteristics and outcomes in women with vulvoâ€vaginal melanoma: A JGOGâ€JSCS joint study. Journal of Surgical Oncology, 2022, 125, 1333-1337.	1.7	0
25	Analysis of postoperative adjuvant therapy in 102 patients with gastric-type mucinous carcinoma of the uterine cervix: A multi-institutional study. European Journal of Surgical Oncology, 2022, , .	1.0	4
26	Zika virus infection and pregnancy outcomes in the United States, 2017â€“2019. International Journal of Gynecology and Obstetrics, 2022, , .	2.3	0
27	Uptake in sentinel lymph node biopsy for endometrial cancer with T3 classification. Gynecologic Oncology, 2022, 165, 361-368.	1.4	4
28	Population incidence and characteristics of secondary breast cancer after uterine cancer: a competing risk analysis. Archives of Gynecology and Obstetrics, 2022, , 1.	1.7	0
29	Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer. Gynecologic Oncology, 2022, 165, 82-89.	1.4	2
30	Association between hospital treatment volume and major complications in ovarian hyperstimulation syndrome. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 272, 240-246.	1.1	0
31	Population-level uptake of neoadjuvant chemotherapy for stage IVB endometrial cancer. Gynecologic Oncology, 2022, 165, 428-436.	1.4	5
32	Trends and characteristics of ovarian conservation at hysterectomy for young women with cervical cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 273, 59-64.	1.1	2
33	Management of Complicated Appendicitis During Pregnancy in the US. JAMA Network Open, 2022, 5, e227555.	5.9	14
34	Substantial variability in ovarian conservation at hysterectomy for endometrial hyperplasia. American Journal of Obstetrics and Gynecology, 2022, 227, 255.e1-255.e18.	1.3	6
35	Sideâ€toâ€end reanastomosis after lowâ€anterior resection (STELAR): Outcomes, feasibility, and description of procedure performed by a gynecologic oncology service. Journal of Surgical Oncology, 2022, 126, 563-570.	1.7	1
36	Utilization and Outcomes of Sentinel Lymph Node Biopsy for Early Endometrial Cancer. Obstetrics and Gynecology, 2022, 139, 809-820.	2.4	14

#	Article	IF	Citations
37	Risk assessment in the patients with uterine cervical cancer harboring intermediate risk factors after radical hysterectomy: a multicenter, retrospective analysis by the Japanese Gynecologic Oncology Group. International Journal of Clinical Oncology, 2022, 27, 1507-1515.	2.2	6
38	Ovarian conservation in a patient with a large ovarian cyst and adnexal torsion â€“ a confirmatory video with intravenous indocyanine green. Fertility and Sterility, 2022, 118, 417-418.	1.0	4
39	Assessment of Severe Maternal Morbidity and Mortality in Pregnancies Complicated by Cancer in the US. JAMA Oncology, 2022, 8, 1213.	7.1	18
40	Association between sentinel lymph node biopsy and micrometastasis in endometrial cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2022, 275, 91-96.	1.1	1
41	Surgical trends in the management of acute cholecystitis during pregnancy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 5752-5759.	2.4	14
42	Utility of the 3-tier grouping system for survival discriminatory ability in stage IIA cervical cancer. European Journal of Surgical Oncology, 2021, 47, 331-337.	1.0	0
43	Uterine carcinosarcoma: Contemporary clinical summary, molecular updates, and future research opportunity. Gynecologic Oncology, 2021, 160, 586-601.	1.4	56
44	Proposal of an endometrial cancer staging schema with stage-specific incorporation of malignant peritoneal cytology. American Journal of Obstetrics and Gynecology, 2021, 224, 319-321.	1.3	12
45	Significance of Malignant Peritoneal Cytology on Survival of Women with Uterine Sarcoma. Annals of Surgical Oncology, 2021, 28, 1740-1748.	1.5	6
46	National trends and outcomes of morbidly obese women who underwent inpatient hysterectomy for benign gynecological disease in the USA. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 459-470.	2.8	11
47	Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer. Gynecologic Oncology, 2021, 160, 32-39.	1.4	20
48	ASO Author Reflections: Spotlight on Malignant Peritoneal Cytology in Uterine Sarcoma: A Potential Avenue for Future Research. Annals of Surgical Oncology, 2021, 28, 1749-1750.	1.5	0
49	Management of recurrent granulosa cell tumor of the ovary: Contemporary literature review and a proposal of hyperthermic intraperitoneal chemotherapy as novel therapeutic option. Journal of Obstetrics and Gynaecology Research, 2021, 47, 44-51.	1.3	7
50	CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma. American Journal of Obstetrics and Gynecology, 2021, 224, 197.e1-197.e23.	1.3	7
51	Rhabdomyolysis following single administration of pembrolizumab: Is severe immune-reaction a marker for durable treatment response?. Gynecologic Oncology Reports, 2021, 35, 100700.	0.6	2
52	Emerging Trends in Neoadjuvant Chemotherapy for Ovarian Cancer. Cancers, 2021, 13, 626.	3.7	26
53	Two distinct mechanisms of neuropathy in immunoglobulin light chain (AL) amyloidosis. Journal of the Neurological Sciences, 2021, 421, 117305.	0.6	6
54	Surgical margin status and recurrence pattern in invasive vulvar Pagetâ€™s disease: A Japanese Gynecologic Oncology Group study. Gynecologic Oncology, 2021, 160, 748-754.	1.4	10

#	Article	IF	Citations
55	Intersection of DNA Repair Pathways and the Immune Landscape Identifies PD-L2 as a Prognostic Marker in Epithelial Ovarian Cancer. Cancers, 2021, 13, 1972.	3.7	0
56	Association Between Adjuvant Therapy and Survival in Stage IIâ€"III Endometrial Cancer: Influence of Malignant Peritoneal Cytology. Annals of Surgical Oncology, 2021, 28, 7591-7603.	1.5	10
57	ASO Author Reflections: Malignant Peritoneal Cytology, Adjuvant Therapy Choice, and Survival in Advanced Endometrial Cancer. Annals of Surgical Oncology, 2021, 28, 7604-7605.	1.5	0
58	Trends, characteristics, and outcomes of placenta accreta spectrum: a national study in the United States. American Journal of Obstetrics and Gynecology, 2021, 225, 534.e1-534.e38.	1.3	78
59	Utilization and perioperative outcome of minimally invasive pelvic exenteration in gynecologic malignancies: A national study in the United States. Gynecologic Oncology, 2021, 161, 39-45.	1.4	13
60	Surgical and oncologic outcomes of hyperthermic intraperitoneal chemotherapy for uterine leiomyosarcoma: A systematic review of literature. Gynecologic Oncology, 2021, 161, 70-77.	1.4	13
61	Laparoscopic pelvic exenteration and laterally extended endopelvic resection for postradiation recurrent cervical carcinoma: Technical feasibility and short-term oncologic outcome. Gynecologic Oncology, 2021, 161, 34-38.	1.4	7
62	Utilization and outcome of systemic chemotherapy for high-risk early-stage cervical cancer.. Journal of Clinical Oncology, 2021, 39, e17521-e17521.	1.6	0
63	Association between definitive chemoradiotherapy wait-time and survival in locally-advanced cervical cancer: Implications during the coronavirus pandemic. Gynecologic Oncology, 2021, 161, 414-421.	1.4	4
64	Recent changes in demographics and outcomes of cervical cancer in the United States. Archives of Gynecology and Obstetrics, 2021, 304, 1-3.	1.7	9
65	Wait-time for adjuvant radiotherapy and oncologic outcome in early-stage cervical cancer: A treatment implication during the coronavirus pandemic. European Journal of Cancer, 2021, 148, 117-120.	2.8	9
66	Utilization and outcomes of adjuvant systemic chemotherapy alone in high risk, early stage cervical cancer in the United States. International Journal of Gynecological Cancer, 2021, 31, 991-1000.	2.5	7
67	Association Between Trimester and Outcomes after Cholecystectomy During Pregnancy. Journal of the American College of Surgeons, 2021, 233, 29-37e1.	0.5	8
68	The validity of the subsequent pregnancy index score for fertility-sparing trachelectomy in early-stage cervical cancer. Fertility and Sterility, 2021, 115, 1250-1258.	1.0	6
69	Ovarian conservation for young women with early-stage, low-grade endometrial cancer: a 2-step schema. American Journal of Obstetrics and Gynecology, 2021, 224, 574-584.	1.3	30
70	Adjuvant hysterectomy following primary chemoradiation for stage IB2 and IIA2 cervical cancer: a retrospective comparison of complications for open versus minimally invasive surgery. Radiation Oncology, 2021, 16, 123.	2.7	1
71	Decreasing Failure-to-Rescue From Severe Maternal Morbidity at Cesarean Delivery. JAMA Surgery, 2021, 156, 585.	4.3	8
72	Clinico-pathological characteristics of patients with stage IB1â€"IB2 (FIGO 2018) uterine cervical cancer: a nationwide study in Japan. International Journal of Clinical Oncology, 2021, 26, 1541-1552.	2.2	4

#	Article	IF	Citations
73	Paradigm shift from tubal ligation to opportunistic salpingectomy at cesarean delivery in the United States. American Journal of Obstetrics and Gynecology, 2021, 225, 399.e1-399.e32.	1.3	24
74	Trends in peritoneal cytology evaluation at hysterectomy for endometrial cancer in the United States. Gynecologic Oncology, 2021, 161, 710-719.	1.4	9
75	Planned supracervical hysterectomy for surgical management of placenta accreta spectrum: A comparative study. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 261, 249-251.	1.1	2
76	Clinicoâ€pathological significance of suspicious peritoneal cytology in endometrial cancer. Journal of Surgical Oncology, 2021, 124, 687-698.	1.7	2
77	CD70 antibodyâ€drug conjugate: A potential novel therapeutic agent for ovarian cancer. Cancer Science, 2021, 112, 3655-3668.	3.9	9
78	Decreasing utilization of minimally invasive hysterectomy for cervical cancer in the United States. Gynecologic Oncology, 2021, 162, 43-49.	1.4	20
79	The influence of obesity on incidence of complications in patients hospitalized with ovarian hyperstimulation syndrome. Archives of Gynecology and Obstetrics, 2021, , 1.	1.7	2
80	Intraoperative Rupture of the Ovarian Capsule in Early-Stage Ovarian Cancer. Obstetrics and Gynecology, 2021, 138, 261-271.	2.4	7
81	Characteristics and outcomes of women with adenocarcinoma versus squamous cell carcinoma of the vulva: A Japanese Gynecologic Oncology Group study. European Journal of Surgical Oncology, 2021, 47, 3188-3193.	1.0	1
82	Predictors of subsequent pregnancy following medical treatment in obese women with complex atypical hyperplasia. Archives of Gynecology and Obstetrics, 2021, , 1.	1.7	0
83	Editor's Note: Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research, 2021, 27, 4450-4450.	7.0	0
84	Editor's Note: Biologic Effects of Platelet-Derived Growth Factor Receptor Î± Blockade in Uterine Cancer. Clinical Cancer Research, 2021, 27, 4449-4449.	7.0	0
85	Immunohistochemical analysis of glassy cell carcinoma of the cervix reveals robust lymphocyte infiltrate and the expression of targetable inhibitory immune checkpoints. Archives of Gynecology and Obstetrics, 2021, , 1.	1.7	0
86	Proposing a molecular classification associated with hypercoagulation in ovarian clear cell carcinoma. Gynecologic Oncology, 2021, 163, 327-333.	1.4	5
87	Risk of Upper-body Adverse Events in Robot-assisted Total Laparoscopic Hysterectomy for Benign Gynecologic Disease. Journal of Minimally Invasive Gynecology, 2021, 28, 1585-1594.e1.	0.6	3
88	Secondary haematologic malignancies in women with ovarian cancer receiving poly-ADP ribose polymerase inhibitor therapy. European Journal of Cancer, 2021, 157, 59-62.	2.8	4
89	Hospital volume-outcome relationship in vulvar cancer treatment: a Japanese Gynecologic Oncology Group study. Journal of Gynecologic Oncology, 2021, 32, e24.	2.2	3
90	Survival effect of intra-operative tumor spillage during minimally invasive hysterectomy for early-stage endometrial cancer: a call for research. International Journal of Gynecological Cancer, 2021, 31, 308-309.	2.5	5

#	Article	IF	Citations
91	Minimally Invasive Surgery and Surgical Volume-Specific Survival and Perioperative Outcome: Unmet Need for Evidence in Gynecologic Malignancy. Journal of Clinical Medicine, 2021, 10, 4787.	2.4	5
92	Utilizations and outcomes of intraâ€arterial balloon occlusion at cesarean hysterectomy for placenta accreta spectrum. Acta Obstetricia Et Gynecologica Scandinavica, 2021, 100, 2234-2243.	2.8	9
93	Proposing the 3â€tier staging system for improving prognostication in Stage I uterine leiomyosarcoma. Journal of Surgical Oncology, 2021, 123, 1099-1108.	1.7	0
94	Intraoperative tumor spill during minimally invasive hysterectomy for endometrial cancer: A survey study on experience and practice. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2021, 267, 256-261.	1.1	5
95	Association between hospital treatment volume and survival of women with gynecologic malignancy in Japan: a JSOG tumor registry-based data extraction study. Journal of Gynecologic Oncology, 2021, 33, .	2.2	4
96	Epigenetic Dysregulation of Trophoblastic Gene Expression in Gestational Trophoblastic Disease. Biomedicines, 2021, 9, 1935.	3.2	7
97	Oncologic Outcomes of Laparoscopic Radical Hysterectomy Using the No-Look No-Touch Technique for Early Stage Cervical Cancer: A Propensity Score-Adjusted Analysis. Cancers, 2021, 13, 6097.	3.7	16
98	Treatment and outcome of placenta percreta: Primary cesarean hysterectomy versus conservative management. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 244, 201-203.	1.1	8
99	Clinical and biological significance of EZH2 expression in endometrial cancer. Cancer Biology and Therapy, 2020, 21, 147-156.	3.4	21
100	Carcinoma of the Ovaries and Fallopian Tubes. , 2020, , 1525-1543.e7.		0
101	Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone. American Journal of Obstetrics and Gynecology, 2020, 222, 484.e1-484.e15.	1.3	16
102	Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecologic Oncology, 2020, 156, 100-106.	1.4	14
103	Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2020, 46, 868-875.	1.0	24
104	Hospital surgical volume and perioperative mortality of pelvic exenteration for gynecologic malignancies. Journal of Surgical Oncology, 2020, 121, 402-409.	1.7	16
105	Vesicoureteral Injury during Benign Hysterectomy: Minimally Invasive Laparoscopic Surgery versus Laparotomy. Journal of Minimally Invasive Gynecology, 2020, 27, 1354-1362.	0.6	15
106	Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate. Gynecologic Oncology, 2020, 156, 341-348.	1.4	22
107	Pathologic and clinical tumor size discordance in early-stage cervical cancer: Does it matter?. Gynecologic Oncology, 2020, 159, 354-358.	1.4	8
108	Reply. American Journal of Obstetrics and Gynecology, 2020, 223, 949-950.	1.3	0

#	Article	IF	Citations
109	Inhibition of poly(ADP-ribose) polymerase induces synthetic lethality in BRIP1 deficient ovarian epithelial cells. Gynecologic Oncology, 2020, 159, 869-876.	1.4	3
110	Minimally invasive radical hysterectomy for early-stage cervical cancer: Volume-outcome relationship in the early experience period. Gynecologic Oncology, 2020, 158, 390-396.	1.4	14
111	Malignant peritoneal cytology and increased mortality risk in stage I non-endometrioid endometrial cancer. Gynecologic Oncology, 2020, 159, 43-51.	1.4	23
112	Safety and Efficacy of Apixaban vs Enoxaparin for Preventing Postoperative Venous Thromboembolism in Women Undergoing Surgery for Gynecologic Malignant Neoplasm. JAMA Network Open, 2020, 3, e207410.	5.9	68
113	Financial viewpoint of minimally invasive radical hysterectomy for early cervical cancer: another disadvantage?. International Journal of Gynecological Cancer, 2020, 30, 1464-1464.	2.5	0
114	Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. International Journal of Gynecological Cancer, 2020, 30, 1-9.	2.5	13
115	Comprehensive Serum Glycopeptide Spectra Analysis Combined with Artificial Intelligence (CSGSA-AI) to Diagnose Early-Stage Ovarian Cancer. Cancers, 2020, 12, 2373.	3.7	12
116	Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929). Clinical Cancer Research, 2020, 26, 5621-5630.	7.0	34
117	Utility of Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA) for the Detection of Early Stage Epithelial Ovarian Cancer. Cancers, 2020, 12, 2374.	3.7	4
118	Effect of delay in surgical therapy for early-stage cervical cancer: An implication in the coronavirus pandemic. European Journal of Cancer, 2020, 139, 173-176.	2.8	9
119	Malignant peritoneal cytology in endometrial cancer: Areas of unmet need for evidence. European Journal of Cancer, 2020, 140, 149-150.	2.8	7
120	Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic. Gynecologic Oncology, 2020, 158, 37-43.	1.4	23
121	Proposal of a Two-Tier System in Grouping Adenocarcinoma of the Uterine Cervix. Cancers, 2020, 12, 1251.	3.7	7
122	Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes. Gynecologic Oncology, 2020, 158, 59-65.	1.4	12
123	Molecular Pathways and Targeted Therapies for Malignant Ovarian Germ Cell Tumors and Sex Cordâ€"Stromal Tumors: A Contemporary Review. Cancers, 2020, 12, 1398.	3.7	24
124	Fertilityâ€sparing treatment for earlyâ€stage epithelial ovarian cancer: Contemporary oncologic, reproductive and endocrinologic perspectives. Journal of Obstetrics and Gynaecology Research, 2020, 46, 1263-1281.	1.3	9
125	Minimally Invasive Surgery and Risk of Capsule Rupture for Women With Early-Stage Ovarian Cancer. JAMA Oncology, 2020, 6, 1110.	7.1	37
126	Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study. Archives of Gynecology and Obstetrics, 2020, 301, 1235-1245.	1.7	6

#	Article	IF	Citations
127	Recurrence Rates in Patients With Cervical Cancer Treated With Abdominal Versus Minimally Invasive Radical Hysterectomy: A Multi-Institutional Retrospective Review Study. Journal of Clinical Oncology, 2020, 38, 1030-1040.	1.6	120
128	Conservative surgery for ovarian torsion in young women: perioperative complications and national trends. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 957-965.	2.3	29
129	Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence. Current Oncology Reports, 2020, 22, 28.	4.0	11
130	Evolving population-based statistics for rare epithelial ovarian cancers. Gynecologic Oncology, 2020, 157, 3-11.	1.4	13
131	Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States. Gynecologic Oncology, 2020, 157, 173-180.	1.4	11
132	Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). Clinical Cancer Research, 2020, 26, 2477-2486.	7.0	16
133	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. Gynecologic Oncology, 2020, 157, 21-28.	1.4	8
134	Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy. American Journal of Obstetrics and Gynecology, 2020, 223, 103.e1-103.e13.	1.3	31
135	Implementation of multidisciplinary practice change to improve outcomes for women with placenta accreta spectrum. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2020, 246, 194-196.	1.1	10
136	Cesarean radical hysterectomy for cervical cancer in the United States: a national study of surgical outcomes. American Journal of Obstetrics and Gynecology, 2020, 222, 507-511.e2.	1.3	4
137	Significance of lymph node ratio on survival of women with borderline ovarian tumors. Archives of Gynecology and Obstetrics, 2020, 301, 1289-1298.	1.7	8
138	A cesarean delivery sequela:. American Journal of Obstetrics and Gynecology, 2020, 223, 582.	1.3	2
139	Delayed hysterectomy versus continuing conservative management for placenta percreta: which is better?. American Journal of Obstetrics and Gynecology, 2020, 223, 304.	1.3	6
140	Minimally invasive interval debulking surgery after neoadjuvant chemotherapy for metastatic ovarian cancer: a national study in the United States. Archives of Gynecology and Obstetrics, 2020, 301, 863-866.	1.7	4
141	The rapid adoption of opportunistic salpingectomy at the time of hysterectomy for benign gynecologic disease in the United States. American Journal of Obstetrics and Gynecology, 2020, 223, 721.e1-721.e18.	1.3	28
142	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. European Journal of Cancer, 2020, 133, 33-46.	2.8	34
143	Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study. , 2020, 80, .		0
144	Utility of the 3-tier grouping system for survival discriminatory ability in stage T2a cervical cancer. , 2020, 80, .		0

#	Article	IF	Citations
145	Malignant peritoneal cytology and decreased survival of women with stage I endometrioid endometrial cancer. , 2020, 80, .		0
146	Reply. American Journal of Obstetrics and Gynecology, 2019, 221, 538.	1.3	0
147	Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. Gynecologic Oncology, 2019, 154, 505-515.	1.4	11
148	Significance of Malignant Peritoneal Cytology on the Survival of Women with Early-Stage Cervical Cancer: A Japanese Gynecologic Oncology Group Study. Journal of Clinical Medicine, 2019, 8, 1822.	2.4	5
149	Dysregulation of Placental Functions and Immune Pathways in Complete Hydatidiform Moles. International Journal of Molecular Sciences, 2019, 20, 4999.	4.1	13
150	Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer. Gynecologic Oncology, 2019, 155, 39-50.	1.4	16
151	Non-prescription cannabis use for symptom management amongst women with gynecologic malignancies. Gynecologic Oncology Reports, 2019, 30, 100497.	0.6	17
152	Effectiveness of progestin-based therapy for morbidly obese women with complex atypical hyperplasia. Archives of Gynecology and Obstetrics, 2019, 299, 801-808.	1.7	14
153	Neoadjuvant Chemotherapy with Taxane and Platinum Followed by Radical Hysterectomy for Stage IB2-IIB Cervical Cancer: Impact of Histology Type on Survival. Journal of Clinical Medicine, 2019, 8, 156.	2.4	12
154	Decreasing Trends of Secondary Primary Colorectal Cancer among Women with Uterine Cancer: A Population-Based Analysis. Journal of Clinical Medicine, 2019, 8, 714.	2.4	3
155	Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis. Gynecologic Oncology, 2019, 154, 169-176.	1.4	8
156	Comprehensive Serum Glycopeptide Spectra Analysis (CSGSA): A Potential New Tool for Early Detection of Ovarian Cancer. Cancers, 2019, 11, 591.	3.7	9
157	Trachelectomy for reproductive-aged women with early-stage cervical cancer: minimally invasive surgery versus laparotomy. American Journal of Obstetrics and Gynecology, 2019, 220, 469.e1-469.e13.	1.3	30
158	Tumor characteristics and outcome of uterine carcinosarcoma in women aged â‰¥80 years. Surgical Oncology, 2019, 29, 25-32.	1.6	1
159	Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer. Gynecologic Oncology, 2019, 154, 45-52.	1.4	15
160	Feasibility and outcome of total laparoscopic radical hysterectomy with no-look no-touch technique for FIGO IB1 cervical cancer. Journal of Gynecologic Oncology, 2019, 30, e71.	2.2	89
161	Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri. Journal of Gynecologic Oncology, 2019, 30, e40.	2.2	31
162	Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. Archives of Gynecology and Obstetrics, 2019, 299, 1641-1649.	1.7	5

#	Article	IF	Citations
163	Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGOâ€"JSOG joint study. Gynecologic Oncology, 2019, 153, 589-596.	1.4	74
164	Utero-ovarian preservation and overall survival of young women with early-stage borderline ovarian tumors. Archives of Gynecology and Obstetrics, 2019, 299, 1651-1658.	1.7	15
165	Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study. Gynecologic Oncology, 2019, 153, 368-375.	1.4	39
166	Survival outcome prediction in cervical cancer: Cox models vs deep-learning model. American Journal of Obstetrics and Gynecology, 2019, 220, 381.e1-381.e14.	1.3	95
167	Predictors for pathological parametrial invasion in clinical stage IIB cervical cancer. European Journal of Surgical Oncology, 2019, 45, 1417-1424.	1.0	10
168	Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes. Gynecologic Oncology, 2019, 153, 230-237.	1.4	16
169	Temporal trends and characteristics of suicide among women with gynecologic malignancy in the United States. Gynecologic Oncology Reports, 2019, 30, 100510.	0.6	6
170	Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstetrics and Gynecology, 2019, 134, 49-57.	2.4	156
171	Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2019, 134, 1017-1026.	2.4	43
172	Emerging serine-threonine kinase inhibitors for treating ovarian cancer. Expert Opinion on Emerging Drugs, 2019, 24, 239-253.	2.4	6
173	Cancer antigen 125 is associated with disease status in uterine carcinosarcoma. Rare Tumors, 2019, 11, 203636131988415.	0.6	3
174	Association of Radical Hysterectomy Surgical Volume and Survival for Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2019, 133, 1086-1098.	2.4	77
175	Changes in the Clinicopathological Demographics of Vulvar Cancer in Japan: Increasing Oldest-Old, Stage Shifting, and Decreasing Cohort-Level Survival â€. Journal of Clinical Medicine, 2019, 8, 2081.	2.4	9
176	Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer. Gynecologic Oncology, 2019, 152, 605-611.	1.4	4
177	Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer. Gynecologic Oncology, 2019, 153, 123-126.	1.4	1
178	Profile of treatment-related complications in women with clinical stage IB-IIB cervical cancer: A nationwide cohort study in Japan. PLoS ONE, 2019, 14, e0210125.	2.5	15
179	Validation of the 2018 FIGO cervical cancer staging system. Gynecologic Oncology, 2019, 152, 87-93.	1.4	203
180	PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer. Molecular Cancer Therapeutics, 2019, 18, 162-172.	4.1	23

#	Article	IF	Citations
181	Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma.. Journal of Clinical Oncology, 2019, 37, 2538-2538.	1.6	81
182	Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases.. Journal of Clinical Oncology, 2019, 37, 5504-5504.	1.6	13
183	Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study. Journal of Gynecologic Oncology, 2019, 30, e113.	2.2	3
184	Role of Para-aortic Lymphadenectomy During Radical Hysterectomy for Stage IBâ€“IIB Cervical Cancer. Comprehensive Gynecology and Obstetrics, 2019, , 183-207.	0.0	0
185	Significance of abnormal peritoneal cytology on survival of women with stage Iâ€“II endometrioid endometrial cancer. Gynecologic Oncology, 2018, 149, 301-309.	1.4	43
186	Fully sialylated alpha-chain of complement 4-binding protein (A2160): a novel prognostic marker for epithelial ovarian carcinoma. Archives of Gynecology and Obstetrics, 2018, 297, 749-756.	1.7	3
187	UPLCâ€MS/MS based diagnostics for epithelial ovarian cancer using fully sialylated C4â€binding protein. Biomedical Chromatography, 2018, 32, e4180.	1.7	3
188	Successful resuscitation after cardiac arrest secondary to carboplatin infusion: A case report. Gynecologic Oncology Reports, 2018, 23, 7-9.	0.6	5
189	Significance of venous thromboembolism in women with uterine carcinosarcoma. Gynecologic Oncology, 2018, 148, 267-274.	1.4	14
190	Development of an oesophageal stimulation method to elicit swallowing reflex in humans. Journal of Oral Rehabilitation, 2018, 45, 211-215.	3.0	2
191	Intrauterine Manipulator Use During Minimally Invasive Hysterectomy and Risk of Lymphovascular Space Invasion in Endometrial Cancer. International Journal of Gynecological Cancer, 2018, 28, 208-219.	2.5	28
192	Malignancy during pregnancy in Japan: an exceptional opportunity for early diagnosis. BMC Pregnancy and Childbirth, 2018, 18, 50.	2.4	16
193	Survival outcome of women with stage IV uterine carcinosarcoma who received neoadjuvant chemotherapy followed by surgery. Journal of Surgical Oncology, 2018, 117, 488-496.	1.7	15
194	Identifying a candidate population for ovarian conservation in young women with clinical stage IBâ€“IIB cervical cancer. International Journal of Cancer, 2018, 142, 1022-1032.	5.1	28
195	Reply. American Journal of Obstetrics and Gynecology, 2018, 218, 264.	1.3	0
196	Aspirin use and endometrial cancer risk and survival. Gynecologic Oncology, 2018, 148, 222-232.	1.4	34
197	Impact of lymphoâ€vascular space invasion on tumor characteristics and survival outcome of women with lowâ€grade serous ovarian carcinoma. Journal of Surgical Oncology, 2018, 117, 236-244.	1.7	8
198	Efficacy of Modified Dose-dense Paclitaxel in Recurrent Cervical Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 851-860.	1.3	6

#	Article	IF	Citations
199	Predictive Value of FDG PET/CT to Detect Lymph Node Metastases in Cervical Cancer. Clinical Nuclear Medicine, 2018, 43, 793-801.	1.3	20
200	Quality and quantity metrics of pelvic lymph node metastasis and risk of para-aortic lymph node metastasis in stage IBâ€"IIB cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e10.	2.2	13
201	Trends in single women with malignancy of the uterine cervix in United States. Journal of Gynecologic Oncology, 2018, 29, e24.	2.2	7
202	Trends of low-grade serous ovarian carcinoma in the United States. Journal of Gynecologic Oncology, 2018, 29, e15.	2.2	29
203	Characteristics and outcomes of reproductive-aged women with early-stage cervical cancer: trachelectomy vs hysterectomy. American Journal of Obstetrics and Gynecology, 2018, 219, 461.e1-461.e18.	1.3	22
204	Clinical utility of CA-125 in the management of uterine carcinosarcoma. Journal of Gynecologic Oncology, 2018, 29, e88.	2.2	4
205	Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. Journal of Gynecologic Oncology, 2018, 29, e91.	2.2	34
206	Trachelectomy for stage IB1 cervical cancer with tumor size >2 cm: trends and characteristics in the United States. Journal of Gynecologic Oncology, 2018, 29, e85.	2.2	11
207	Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management. Gynecologic Oncology, 2018, 151, 381-389.	1.4	99
208	Teenage pregnancy complicated by primary invasive ovarian cancer: association for oncologic outcome. Journal of Gynecologic Oncology, 2018, 29, e79.	2.2	1
209	Risk stratification models for para-aortic lymph node metastasis and recurrence in stage IBâ€"IIB cervical cancer. Journal of Gynecologic Oncology, 2018, 29, e11.	2.2	34
210	Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer. Gynecologic Oncology, 2018, 151, 250-256.	1.4	4
211	Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element. Surgical Oncology, 2018, 27, 433-440.	1.6	12
212	Prolonged intubation after robotic-assisted hysterectomy for endometrial cancer: Case reports. Gynecologic Oncology Reports, 2018, 25, 106-108.	0.6	2
213	Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis. Gynecologic Oncology, 2018, 150, 501-508.	1.4	11
214	Adequate pelvic lymphadenectomy and survival of women with early-stage epithelial ovarian cancer. Journal of Gynecologic Oncology, 2018, 29, e69.	2.2	27
215	Significance of Lymphovascular Space Invasion by the Sarcomatous Component in Uterine Carcinosarcoma. Annals of Surgical Oncology, 2018, 25, 2756-2766.	1.5	5
216	Trends of uterine carcinosarcoma in the United States. Journal of Gynecologic Oncology, 2018, 29, e22.	2.2	47

#	Article	IF	Citations
217	Nivolumab use for BRCA gene mutation carriers with recurrent epithelial ovarian cancer: A case series. Gynecologic Oncology Reports, 2018, 25, 98-101.	0.6	23
218	Proposal for a Risk-Based Categorization of Uterine Carcinosarcoma. Annals of Surgical Oncology, 2018, 25, 3676-3684.	1.5	14
219	Trends and outcomes of women with synchronous endometrial and ovarian cancer. Oncotarget, 2018, 9, 28757-28771.	1.8	38
220	Overexpression of HOMER2 predicts better outcome in low-grade endometrioid endometrial adenocarcinoma. Pathology, 2018, 50, 499-503.	0.6	5
221	A phase 2 biomarker trial of combination cediranib and olaparib in relapsed platinum (plat) sensitive and plat resistant ovarian cancer (ovca).. Journal of Clinical Oncology, 2018, 36, 5519-5519.	1.6	11
222	A phase 2, multicenter study to evaluate the efficacy and safety using autologous tumor infiltrating lymphocytes (LN-145) in patients with recurrent, metastatic, or persistent cervical carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS5604-TPS5604.	1.6	4
223	Race and nodal disease status are prognostic factors in patients with stage IVB cervical cancer. Oncotarget, 2018, 9, 32321-32330.	1.8	10
224	Phase II clinical trial of eribulin (E) in advanced/recurrent cervical cancer.. Journal of Clinical Oncology, 2018, 36, 5526-5526.	1.6	0
225	Tumor characteristics and survival outcomes of women with tamoxifen-related uterine carcinosarcoma. Gynecologic Oncology, 2017, 144, 329-335.	1.4	20
226	Significance of lymph node metastasis on survival of women with uterine adenosarcoma. Gynecologic Oncology, 2017, 144, 524-530.	1.4	36
227	Role of hysterectomy and lymphadenectomy in the management of early-stage borderline ovarian tumors. Gynecologic Oncology, 2017, 144, 496-502.	1.4	27
228	Significance of uterine corpus tumor invasion in early-stage cervical cancer. European Journal of Surgical Oncology, 2017, 43, 725-734.	1.0	29
229	Prognosis of women with apparent stage I endometrial cancer who had supracervical hysterectomy. Gynecologic Oncology, 2017, 145, 41-49.	1.4	3
230	Impact of adjuvant therapy on recurrence patterns in stage I uterine carcinosarcoma. Gynecologic Oncology, 2017, 145, 78-87.	1.4	31
231	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Cervical Cancer. Obstetrics and Gynecology, 2017, 129, 139-151.	2.4	31
232	Endometrial cancer arising in adenomyosis versus endometrial cancer coexisting with adenomyosis: are these two different entities?. Archives of Gynecology and Obstetrics, 2017, 295, 1459-1468.	1.7	29
233	Comparison of adjuvant therapy for nodeâ€positive clinical stage IBâ€IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation. International Journal of Cancer, 2017, 141, 1042-1051.	5.1	59
234	Patient compliance for postoperative radiotherapy and survival outcome of women with stage I endometrioid endometrial cancer. Journal of Surgical Oncology, 2017, 116, 482-491.	1.7	11

#	Article	IF	Citations
235	Incidence of urinary tract injury and utility of routine cystoscopy during total laparoscopic hysterectomy for endometrial cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2017, 213, 141-142.	1.1	5
236	Extent of pelvic lymphadenectomy and use of adjuvant vaginal brachytherapy for early-stage endometrial cancer. Gynecologic Oncology, 2017, 144, 515-523.	1.4	10
237	Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer. Gynecologic Oncology, 2017, 147, 558-564.	1.4	37
238	Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma. Gynecologic Oncology, 2017, 147, 565-571.	1.4	9
239	Association of Metformin Use and Survival Outcome in Women With Cervical Cancer. International Journal of Gynecological Cancer, 2017, 27, 1455-1463.	2.5	14
240	Significance of Monocyte Counts at Recurrence on Survival Outcome of Women With Endometrial Cancer. International Journal of Gynecological Cancer, 2017, 27, 302-310.	2.5	19
241	Single Marital Status and Infectious Mortality in Women With Cervical Cancer in the United States. International Journal of Gynecological Cancer, 2017, 27, 1737-1746.	2.5	8
242	Endometrioid Adenocarcinoma Arising in a Paratubal Cyst: A Case Report and Review of the Literature. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, e21-e24.	1.2	4
243	Predictive model of urinary tract infection after surgical treatment for women with endometrial cancer. Archives of Gynecology and Obstetrics, 2017, 296, 335-343.	1.7	1
244	Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer. Obstetrics and Gynecology, 2017, 130, 403-410.	2.4	33
245	Risk of metachronous ovarian cancer after ovarian conservation in young women with stage I cervical cancer. American Journal of Obstetrics and Gynecology, 2017, 217, 580.e1-580.e10.	1.3	19
246	Transforming growth factorâ€Î² signaling is upregulated in sporadic inclusion body myositis. Muscle and Nerve, 2017, 55, 741-747.	2.2	9
247	Association of Nonalcoholic Fatty Liver Disease and Venous Thromboembolism in Women With Endometrial Cancer. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 1018-1027.	1.7	7
248	A pilot study in using deep learning to predict limited life expectancy in women with recurrent cervical cancer. American Journal of Obstetrics and Gynecology, 2017, 217, 703-705.	1.3	19
249	Ovarian conservation for young women with clinical stage IBâ€"IIB cervical cancer in Japan. Journal of Gynecologic Oncology, 2017, 28, e60.	2.2	8
250	Diagnosis and Management of Vulvar Cancer. , 2017, , 789-806.		3
251	Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. Oncotarget, 2017, 8, 106866-106875.	1.8	30
252	Diagnosis and Management of Nonepithelial Ovarian Cancer. , 2017, , 933-957.		0

#	Article	IF	Citations
253	Management of Cervical Dysplasia. , 2017, , 865-875.		2
254	Diagnosis and Management of Vulvar Cancer. , 2017, , 1-18.		0
255	Diagnosis and Management of Gestational Trophoblastic Disease. , 2017, , 773-787.		0
256	Preinvasive Epithelial Disease of the Vulvar. , 2017, , 969-981.		0
257	Phase II study of cabozantinib (cabo) in patients (pts) with recurrent/metastatic endometrial cancer (EC): A study of the Princess Margaret, Chicago, and California phase II consortia.. Journal of Clinical Oncology, 2017, 35, 5524-5524.	1.6	2
258	Exploratory phase II evaluation of cabozantinib in recurrent/metastatic uterine carcinosarcoma (CS): A study of the Princess Margaret, Chicago, and California phase II consortia.. Journal of Clinical Oncology, 2017, 35, 5587-5587.	1.6	1
259	Surgical menopause and increased risk of nonalcoholic fatty liver disease in endometrial cancer. Menopause, 2016, 23, 189-196.	2.0	51
260	Signs and Symptoms of Venous Thromboembolism and Survival Outcome of Endometrial Cancer. International Journal of Gynecological Cancer, 2016, 26, 924-932.	2.5	6
261	Timing of Intrauterine Manipulator Insertion During Minimally Invasive Surgical Staging and Results of Pelvic Cytology in Endometrial Cancer. Journal of Minimally Invasive Gynecology, 2016, 23, 234-241.	0.6	25
262	Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer. Obstetrics and Gynecology, 2016, 128, 761-770.	2.4	56
263	Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma. Annals of Oncology, 2016, 27, 1257-1266.	1.2	65
264	Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature. Expert Opinion on Investigational Drugs, 2016, 25, 781-796.	4.1	12
265	Significance of venous thromboembolism in women with cervical cancer. Gynecologic Oncology, 2016, 142, 405-412.	1.4	20
266	Association of Low-Dose Aspirin and Survival of Women With Endometrial Cancer. Obstetrics and Gynecology, 2016, 128, 127-137.	2.4	39
267	Single-dose intra-arterial neoadjuvant chemotherapy while waiting for radical hysterectomy for stage IB-IIB cervical cancer. Molecular and Clinical Oncology, 2016, 4, 1068-1072.	1.0	2
268	Contributing factors for menopausal symptoms after surgical staging for endometrial cancer. Menopause, 2016, 23, 535-543.	2.0	8
269	In Reply to the Letter to the Editor on Matsuo et al. â€œTreatment patterns and survival outcomes in patients with cervical cancer complicated by complete uterine prolapse: a systematic review of literatureâ€. International Urogynecology Journal, 2016, 27, 1285-1286.	1.4	0
270	Weight Change Pattern and Survival Outcome of Women with Endometrial Cancer. Annals of Surgical Oncology, 2016, 23, 2988-2997.	1.5	22

#	Article	IF	Citations
271	Treatment patterns and survival outcomes in patients with cervical cancer complicated by complete uterine prolapse: a systematic review of literature. International Urogynecology Journal, 2016, 27, 29-38.	1.4	20
272	Predictive Factor of Conversion to Laparotomy in Minimally Invasive Surgical Staging for Endometrial Cancer. International Journal of Gynecological Cancer, 2016, 26, 290-300.	2.5	9
273	Feto-maternal outcomes of pregnancy complicated by Krukenberg tumor: a systematic review of literature. Archives of Gynecology and Obstetrics, 2016, 294, 589-598.	1.7	12
274	Tumor Characteristics and Survival Outcome of Endometrial Cancer Arising in Adenomyosis: An Exploratory Analysis. Annals of Surgical Oncology, 2016, 23, 959-967.	1.5	25
275	Associations between oral complications and days to death in palliative care patients. Supportive Care in Cancer, 2016, 24, 157-161.	2.2	29
276	SSRI use and clinical outcomes in epithelial ovarian cancer. Oncotarget, 2016, 7, 33179-33191.	1.8	26
277	Diagnosis and Management of Vulvar Cancer. , 2016, , 1-18.		0
278	Preinvasive Epithelial Disease of the Vulvar. , 2016, , 1-14.		0
279	Diagnosis and Management of Nonepithelial Ovarian Cancer. , 2016, , 1-25.		0
280	Management of Cervical Dysplasia. , 2016, , 1-11.		0
281	Clinical impact of selective and nonselective betaâ€blockers on survival in patients with ovarian cancer. Cancer, 2015, 121, 3444-3451.	4.1	157
282	Relative Morbidity and Mortality of Panniculectomy-Combined Surgical Staging in Endometrial Cancer. International Journal of Gynecological Cancer, 2015, 25, 1503-1512.	2.5	8
283	Impact of depth and extent of lymphovascular space invasion on lymph node metastasis and recurrence patterns in endometrial cancer. Journal of Surgical Oncology, 2015, 112, 669-676.	1.7	42
284	In Reply. Obstetrics and Gynecology, 2015, 125, 1498.	2.4	2
285	Clinical implication of surgically treated early-stage cervical cancer with multiple high-risk factors. Journal of Gynecologic Oncology, 2015, 26, 3.	2.2	20
286	Significance of monocyte counts on tumor characteristics and survival outcome of women with endometrial cancer. Gynecologic Oncology, 2015, 138, 332-338.	1.4	35
287	Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new. Journal of Clinical Pathology, 2015, 68, 710-717.	2.0	30
288	Intraocular metastasis from primary cervical cancer: A case report and review of the literature. Gynecologic Oncology Reports, 2015, 12, 61-63.	0.6	3

#	Article	IF	Citations
289	Survival outcome of stage I ovarian clear cell carcinoma with lympho-vascular space invasion. Gynecologic Oncology, 2015, 136, 198-204.	1.4	17
290	Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 186, 97-105.	1.1	31
291	Characteristics of ovarian tumors of low malignant potential in BRCA mutation carriers: A case series. Gynecologic Oncology Reports, 2015, 13, 36-39.	0.6	6
292	Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. British Journal of Cancer, 2015, 113, 817-826.	6.4	111
293	Time Interval Between Endometrial Biopsy and Surgical Staging for Type I Endometrial Cancer. Obstetrics and Gynecology, 2015, 125, 424-433.	2.4	53
294	The significance of lymphatic space invasion and its association with vascular endothelial growth factor-C expression in ovarian cancer. Clinical and Experimental Metastasis, 2015, 32, 789-798.	3.3	7
295	Effects of imiquimod on vulvar Paget's disease: A systematic review of literature. Gynecologic Oncology, 2015, 139, 165-171.	1.4	59
296	Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell, 2015, 28, 610-622.	16.8	94
297	Fully-sialylated alpha-chain of complement 4-binding protein: Diagnostic utility for ovarian clear cell carcinoma. Gynecologic Oncology, 2015, 139, 520-528.	1.4	17
298	Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecologic Oncology, 2015, 139, 261-267.	1.4	51
299	Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C. Clinical Immunology, 2015, 161, 197-208.	3.2	21
300	Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma. European Journal of Cancer, 2015, 51, 1978-1988.	2.8	44
301	Vitamin E intake from natural sources and head and neck cancer risk: a pooled analysis in the International Head and Neck Cancer Epidemiology consortium. British Journal of Cancer, 2015, 113, 182-192.	6.4	24
302	Adrenergic regulation of monocyte chemotactic protein 1 leads to enhanced macrophage recruitment and ovarian carcinoma growth. Oncotarget, 2015, 6, 4266-4273.	1.8	78
303	Phase II clinical trial of eribulin in advanced or recurrent cervical cancer (CC).. Journal of Clinical Oncology, 2015, 33, TPS5617-TPS5617.	1.6	0
304	Significance of Adenomyosis on Tumor Progression and Survival Outcome of Endometrial Cancer. Annals of Surgical Oncology, 2014, 21, 4246-4255.	1.5	35
305	Suppression of acetylpolyamine oxidase by selected AP-1 members regulates DNp73 abundance: mechanistic insights for overcoming DNp73-mediated resistance to chemotherapeutic drugs. Cell Death and Differentiation, 2014, 21, 1240-1249.	11.2	29
306	Association of vegetable and fruit intake with gastric cancer risk among Japanese: a pooled analysis of four cohort studies. Annals of Oncology, 2014, 25, 1228-1233.	1.2	47

#	Article	IF	Citations
307	Snowman sign: a possible predictor of catastrophic abnormal placentation. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 181, 341-342.	1.1	14
308	Biologic Effects of Platelet-Derived Growth Factor Receptor Î± Blockade in Uterine Cancer. Clinical Cancer Research, 2014, 20, 2740-2750.	7.0	14
309	Effect of Lymphovascular Space Invasion on Survival of Stage I Epithelial Ovarian Cancer. Obstetrics and Gynecology, 2014, 123, 957-965.	2.4	17
310	Feto-maternal outcome of pregnancy complicated by vulvar cancer: a systematic review of literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 179, 216-223.	1.1	28
311	Feto-maternal outcomes of pregnancy complicated by ovarian sex-cord stromal tumor: a systematic review of literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 175, 1-7.	1.1	27
312	Estrogen receptor expression and increased risk of lymphovascular space invasion in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2014, 133, 473-479.	1.4	53
313	Cervical conization of adenocarcinoma in situ: a predicting model of residual disease. American Journal of Obstetrics and Gynecology, 2014, 210, 366.e1-366.e5.	1.3	24
314	Feto-maternal outcomes of pregnancy complicated by ovarian malignant germ cell tumor: a systematic review of literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 181, 145-156.	1.1	31
315	Clinical characteristics and outcomes of uterine tumors resembling ovarian sex-cord tumors (UTROSCT): a systematic review of literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 181, 163-170.	1.1	65
316	Toe metastasis: A rare pattern of cervical cancer spread. Gynecologic Oncology Case Reports, 2014, 8, 7-9.	0.9	5
317	Platelet-derived growth factor receptor alpha (PDGFRÎ±) targeting and relevant biomarkers in ovarian carcinoma. Gynecologic Oncology, 2014, 132, 166-175.	1.4	31
318	SAT0560â€…The in Vivo Role of Bone Specific Ephb4 Receptor Overexpression in Osteoarthritic Synovial Membrane. Annals of the Rheumatic Diseases, 2014, 73, 793.1-793.	0.9	0
319	Therapeutic Synergy between microRNA and siRNA in Ovarian Cancer Treatment. Cancer Discovery, 2013, 3, 1302-1315.	9.4	140
320	The endoplasmic reticulum stress marker, glucose-regulated protein-78 (GRP78) in visceral adipocytes predicts endometrial cancer progression and patient survival. Gynecologic Oncology, 2013, 128, 552-559.	1.4	60
321	Biological significance of HORMA domain containing protein 1 (HORMAD1) in epithelial ovarian carcinoma. Cancer Letters, 2013, 330, 123-129.	7.2	26
322	Biologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma. Neoplasia, 2013, 15, 502-IN15.	5.3	66
323	Predictive model of venous thromboembolism in endometrial cancer. Gynecologic Oncology, 2013, 128, 544-551.	1.4	55
324	Inferior Vena Cava Filter Placement and Risk of Hematogenous Distant Metastasis in Ovarian Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 362-367.	1.3	23

#	Article	IF	Citations
325	Utility of risk-weighted surgicalâ€"pathological factors in early-stage cervical cancer. British Journal of Cancer, 2013, 108, 1348-1357.	6.4	17
326	Long-Term Pegylated Liposomal Doxorubicin Use and Oromaxillary Squamous Cell Carcinoma in Endometrial Cancer. Oncologist, 2012, 17, 1598-1599.	3.7	13
327	Paraneoplastic Thrombocytosis in Ovarian Cancer. New England Journal of Medicine, 2012, 366, 610-618.	27.0	651
328	Cot Kinase Promotes Ca²⁺ Oscillation/Calcineurin-Independent Osteoclastogenesis by Stabilizing NFATc1 Protein. Molecular and Cellular Biology, 2012, 32, 2954-2963.	2.3	20
329	Significance of Perioperative Infection in Survival of Patients With Ovarian Cancer. International Journal of Gynecological Cancer, 2012, 22, 245-253.	2.5	34
330	Comparison of the Prognoses of FIGO Stage I to Stage II Adenosquamous Carcinoma and Adenocarcinoma of the Uterine Cervix Treated With Radical Hysterectomy. International Journal of Gynecological Cancer, 2012, 22, 1389-1397.	2.5	25
331	Successful extraction of cardiac-extending intravenous leiomyomatosis through gonadal vein. Fertility and Sterility, 2012, 98, 1341-1345.e1.	1.0	18
332	Impact of histological subtype on survival of patients with surgically-treated stage IA2â€"IIB cervical cancer: Adenocarcinoma versus squamous cell carcinoma. Gynecologic Oncology, 2012, 127, 114-120.	1.4	82
333	Leiomyomatoid angiomatous neuroendocrine tumor of the uterine myometrium with synchronous renal leiomyosarcoma: case report and review of the literature. International Cancer Conference Journal, 2012, 1, 243-250.	0.5	1
334	Significance of lymphovascular space invasion in epithelial ovarian cancer. Cancer Medicine, 2012, 1, 156-164.	2.8	40
335	Endometriosis in para-aortic lymph nodes during pregnancy: case report and review of literature. Fertility and Sterility, 2011, 95, 2429.e9-2429.e13.	1.0	11
336	Multidrug Resistance Gene (MDR-1) and Risk of Brain Metastasis in Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 488-493.	1.3	31
337	Radical hysterectomy with adjuvant radiotherapy versus definitive radiotherapy alone for FIGO stage IIB cervical cancer. Gynecologic Oncology, 2011, 123, 241-247.	1.4	44
338	Targeting Src in Mucinous Ovarian Carcinoma. Clinical Cancer Research, 2011, 17, 5367-5378.	7.0	42
339	Patient-Reported Symptoms and Survival in Ovarian Cancer. International Journal of Gynecological Cancer, 2011, 21, 1555-1565.	2.5	8
340	Biological Roles of the Delta Family Notch Ligand Dll4 in Tumor and Endothelial Cells in Ovarian Cancer. Cancer Research, 2011, 71, 6030-6039.	0.9	92
341	Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 358-363.	1.3	22
342	Chemotherapy time interval and development of platinum and taxane resistance in ovarian, fallopian, and peritoneal carcinomas. Archives of Gynecology and Obstetrics, 2010, 281, 325-328.	1.7	28

#	Article	IF	Citations
343	Amputation of uterine corpus as the intraoperative modification during cesarean radical hysterectomy for invasive cervical cancer during pregnancy. International Journal of Clinical Oncology, 2010, 15, 77-81.	2.2	3
344	Increased paclitaxel resistance in recurrent epithelial ovarian cancer: analysis of metachronous tumors. International Journal of Clinical Oncology, 2010, 15, 325-327.	2.2	1
345	Regulation of Tumor Angiogenesis by EZH2. Cancer Cell, 2010, 18, 185-197.	16.8	346
346	Clinical relevance of extent of extreme drug resistance in epithelial ovarian carcinoma. Gynecologic Oncology, 2010, 116, 61-65.	1.4	47
347	Area of uncertainty in uterine arterial embolization: Does it increase the risk of ovarian cancer?. Journal of Obstetrics and Gynaecology Research, 2010, 36, 920-920.	1.3	0
348	Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer. Molecular Cancer Therapeutics, 2010, 9, 985-995.	4.1	51
349	Overcoming platinum resistance in ovarian carcinoma. Expert Opinion on Investigational Drugs, 2010, 19, 1339-1354.	4.1	95
350	Sustained Small Interfering RNA Delivery by Mesoporous Silicon Particles. Cancer Research, 2010, 70, 3687-3696.	0.9	313
351	Elective cesarean delivery at 38Âweeks' gestation: Is the timing too early?. Journal of Perinatal Medicine, 2009, 37, 569.	1.4	0
352	Vulvar Mucinous Adenocarcinoma Associated with Crohnâ€™s Disease: Report of Two Cases. Gynecologic and Obstetric Investigation, 2009, 68, 276-278.	1.6	6
353	Decreased placental oxygenation capacity in pre-eclampsia: clinical application of a novel index of placental function preformed at the time of delivery. Journal of Perinatal Medicine, 2009, 37, 657-661.	1.4	11
354	Umbilical Arterial-Venous Blood Gas Difference: A Novel Expression of Placental Respiratory Function. American Journal of Perinatology, 2009, 26, 199-206.	1.4	7
355	Massive Retroperitoneal Cyst during Pregnancy: Case Report Managed Conservatively by Percutaneous Aspiration and Review of Literature. American Journal of Perinatology, 2009, 26, 215-219.	1.4	0
356	Pregnancy and Genital Sarcoma: A Systematic Review of the Literature. American Journal of Perinatology, 2009, 26, 507-518.	1.4	18
357	Low drug resistance to both platinum and taxane chemotherapy on an in vitro drug resistance assay predicts improved survival in patients with advanced epithelial ovarian, fallopian and peritoneal cancer. International Journal of Cancer, 2009, 125, 2721-2727.	5.1	34
358	Primary peritoneal clear cell adenocarcinoma arising in previous abdominal scar for endometriosis surgery. Archives of Gynecology and Obstetrics, 2009, 280, 637-641.	1.7	24
359	Use of uterine fundal pressure maneuver at vaginal delivery and risk of severe perineal laceration. Archives of Gynecology and Obstetrics, 2009, 280, 781-786.	1.7	48
360	Parental aging synergistically decreases offspring sex ratio. Journal of Obstetrics and Gynaecology Research, 2009, 35, 164-168.	1.3	21

#	Article	IF	Citations
361	Duration of the second stage of labor while wearing a dental support device: A pilot study. Journal of Obstetrics and Gynaecology Research, 2009, 35, 672-678.	1.3	7
362	Clitoral metastasis of anal adenocarcinoma associated with rectovaginal fistula in long standing Crohn's disease. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 144, 182-183.	1.1	8
363	Hydatidiform mole co-existing with cervical cancer: Case report and review of literature. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 146, 108-109.	1.1	0
364	Headaches in pre-eclampsia: A clinical dilemma in diagnosing intracranial hemorrhage. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2009, 146, 232-233.	1.1	6
365	Ultrasonic surgical aspiration for vaginal intraepithelial neoplasia. International Journal of Gynecology and Obstetrics, 2009, 105, 71-73.	2.3	20
366	Different expression of progesterone receptor between uterine serous carcinoma and ovarian serous carcinoma. Journal of Clinical Oncology, 2009, 27, 5578-5578.	1.6	0
367	Anaphylactoid syndrome of pregnancy immediately after intrauterine pressure catheter placement. American Journal of Obstetrics and Gynecology, 2008, 198, e8-e9.	1.3	42
368	The big seep. American Journal of Obstetrics and Gynecology, 2008, 198, 145.e1-145.e2.	1.3	0
369	A rapid-growing uterine mass during pregnancy. American Journal of Obstetrics and Gynecology, 2008, 199, 440.e1-440.e2.	1.3	1
370	Outcomes of hysterectomies performed by supervised residents vs those performed by attendings alone. American Journal of Obstetrics and Gynecology, 2008, 199, 673.e1-673.e6.	1.3	16
371	Maternal urinoma during pregnancy. Journal of Obstetrics and Gynaecology Research, 2008, 34, 88-91.	1.3	5
372	Staircase sign: A newly described uterine contraction pattern seen in rupture of unscarred gravid uterus. Journal of Obstetrics and Gynaecology Research, 2008, 34, 100-104.	1.3	14
373	Is 38Âweeks late enough for elective cesarean delivery?. International Journal of Gynecology and Obstetrics, 2008, 100, 90-91.	2.3	9
374	Osteoblasts induce Ca ²⁺ oscillation-independent NFATc1 activation during osteoclastogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8643-8648.	7.1	134
375	Binding of plasminogen to hepatocytes isolated from injured mice liver and nonparenchymal cell-dependent proliferation of hepatocytes. Blood Coagulation and Fibrinolysis, 2008, 19, 503-511.	1.0	8
376	Late Postpartum Eclampsia: Report of Two Cases Managed by Uterine Curettage and Review of the Literature. American Journal of Perinatology, 2007, 24, 257-266.	1.4	39
377	Hyperemesis Gravidarum in Eastern Asian Population. Gynecologic and Obstetric Investigation, 2007, 64, 213-216.	1.6	38
378	Alport Syndrome and Pregnancy. Obstetrics and Gynecology, 2007, 109, 531-532.	2.4	22

#	Article	IF	Citations
379	Increased leukocyte distribution in the preâ€clinical stage of preâ€eclampsia. International Journal of Gynecology and Obstetrics, 2007, 96, 31-32.	2.3	8
380	Maternal positioning and fetal positioning in utero. Journal of Obstetrics and Gynaecology Research, 2007, 33, 279-282.	1.3	8
381	Uterine varices during pregnancy. American Journal of Obstetrics and Gynecology, 2007, 197, 112.e1.	1.3	4
382	Randomized phase III trial of docetaxel and cisplatin combination chemotherapy versus mitomycin, vindesine and cisplatin combination chemotherapy with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer: Preliminary report. Journal of Clinical Oncology, 2006, 24, 7101-7101.	1.6	2
383	Tension-free vaginal tape procedure with manual-tapping method: A potentially useful technique. Journal of Obstetrics and Gynaecology Research, 2005, 31, 247-251.	1.3	0
384	Cyclic Motion of the Soft Palate in Feeding. Journal of Dental Research, 2005, 84, 39-42.	5.2	31
385	Idarubicin Administered during Pregnancy: Its Effects on the Fetus. Gynecologic and Obstetric Investigation, 2004, 58, 186-188.	1.6	31
386	Uterine rupture of cesarean scar related to spontaneous abortion in the first trimester. Journal of Obstetrics and Gynaecology Research, 2004, 30, 34-36.	1.3	28
387	Decreased cerebral haemodynamic response to cognitive and physiological tasks in mood disorders as shown by near-infrared spectroscopy. Psychological Medicine, 2002, 32, 1029-1037.	4.5	144
388	Mechanism of Antiarrhythmic Effects of Class Ic Drugs in Paroxysmal Atrial Fibrillation in Man. Cardiology, 1998, 89, 119-123.	1.4	9
389	Effects of an Angiotensin II Antagonist on Reperfusion Arrhythmias in Dogs. PACE - Pacing and Clinical Electrophysiology, 1997, 20, 938-945.	1.2	20
390	ATP release and contraction mediated by different P2-receptor subtypes in guinea-pig ileal smooth muscle. British Journal of Pharmacology, 1997, 121, 1744-1748.	5.4	43
391	Detection of Burstâ€promoting Activity in Spleens of Myeloproliferative Sarcoma Virusâ€infected Mice Using Serumâ€free Cultures. Pathology International, 1991, 41, 259-264.	1.3	1
392	Preoperative bowel prepalation using peroral polyethylene glycol electolyte solution and the effect on the body flood.. Nihon Daicho Komonbyo Gakkai Zasshi, 1990, 43, 337-342.	0.0	0
393	Influence of alcohol intake, cigarette smoking, and occupational status on idiopathic osteonecrosis of the femoral head. Clinical Orthopaedics and Related Research, 1988, , 115-23.	1.5	57